BACKGROUND AND PURPOSE: Erythropoietin (EPO) confers potent neuroprotection against ischemic injury. However, treatment for stroke requires high doses and multiple administrations of EPO, which may cause deleterious side effects due to its erythropoietic activity. This study identifies a novel nonerythropoietic mutant EPO and investigates its potential neuroprotective effects and underlying mechanism in an animal model of cerebral ischemia. METHODS: We constructed a series of mutant EPOs, each containing a single amino acid mutation within the erythropoietic motif, and tested their erythropoietic activity. Using cortical neuronal cultures exposed to N-methyl-d-aspartate neurotoxicity and a murine model of transient middle cerebral artery occlusion, neuroprotection and neurofunctional outcomes were assessed as well as activation of intracellular signaling pathways. RESULTS: The serine to isoleucine mutation at position 104 (S104I-EPO) completely abolished the erythropoietic and platelet-stimulating activity of EPO. Administration of S104I-EPO significantly inhibited N-methyl-d-aspartate-induced neuronal death in primary cultures and protected against cerebral infarction and neurological deficits with an efficacy similar to that of wild-type EPO. Both S104-I-EPO and wild-type EPO activated similar prosurvival signaling pathways such as phosphatidylinositol 3-kinase/AKT, mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2, and STAT5. Inhibition of phosphatidylinositol 3-kinase/AKT or mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 signaling pathways significantly attenuated the neuroprotective effects of S104-I-EPO, indicating that activation of these pathways underlies the neuroprotective mechanism of mutant EPO against cerebral ischemia. CONCLUSIONS: S104-I-EPO confers neuroprotective effects comparable to those of wild-type EPO against ischemic brain injury with the added benefit of lacking erythropoietic and platelet-stimulating side effects. Our novel findings suggest that the nonerythropoietic mutant EPO is a legitimate candidate for ischemic stroke intervention.
BACKGROUND AND PURPOSE:Erythropoietin (EPO) confers potent neuroprotection against ischemic injury. However, treatment for stroke requires high doses and multiple administrations of EPO, which may cause deleterious side effects due to its erythropoietic activity. This study identifies a novel nonerythropoietic mutant EPO and investigates its potential neuroprotective effects and underlying mechanism in an animal model of cerebral ischemia. METHODS: We constructed a series of mutant EPOs, each containing a single amino acid mutation within the erythropoietic motif, and tested their erythropoietic activity. Using cortical neuronal cultures exposed to N-methyl-d-aspartateneurotoxicity and a murine model of transient middle cerebral artery occlusion, neuroprotection and neurofunctional outcomes were assessed as well as activation of intracellular signaling pathways. RESULTS: The serine to isoleucine mutation at position 104 (S104I-EPO) completely abolished the erythropoietic and platelet-stimulating activity of EPO. Administration of S104I-EPO significantly inhibited N-methyl-d-aspartate-induced neuronal death in primary cultures and protected against cerebral infarction and neurological deficits with an efficacy similar to that of wild-type EPO. Both S104-I-EPO and wild-type EPO activated similar prosurvival signaling pathways such as phosphatidylinositol 3-kinase/AKT, mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2, and STAT5. Inhibition of phosphatidylinositol 3-kinase/AKT or mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 signaling pathways significantly attenuated the neuroprotective effects of S104-I-EPO, indicating that activation of these pathways underlies the neuroprotective mechanism of mutant EPO against cerebral ischemia. CONCLUSIONS:S104-I-EPO confers neuroprotective effects comparable to those of wild-type EPO against ischemic brain injury with the added benefit of lacking erythropoietic and platelet-stimulating side effects. Our novel findings suggest that the nonerythropoietic mutant EPO is a legitimate candidate for ischemic stroke intervention.
Authors: Ertugrul Kilic; Ulkan Kilic; Jorge Soliz; Claudio L Bassetti; Max Gassmann; Dirk M Hermann Journal: FASEB J Date: 2005-10-05 Impact factor: 5.191
Authors: Feng Zhang; Juan Xing; Anthony Kian-Fong Liou; Suping Wang; Yu Gan; Yumin Luo; Xuming Ji; R Anne Stetler; Jun Chen; Guodong Cao Journal: Transl Stroke Res Date: 2010-06 Impact factor: 6.829
Authors: M Sakanaka; T C Wen; S Matsuda; S Masuda; E Morishita; M Nagao; R Sasaki Journal: Proc Natl Acad Sci U S A Date: 1998-04-14 Impact factor: 11.205
Authors: Marcel Leist; Pietro Ghezzi; Giovanni Grasso; Roberto Bianchi; Pia Villa; Maddalena Fratelli; Costanza Savino; Marina Bianchi; Jacob Nielsen; Jens Gerwien; Pekka Kallunki; Anna Kirstine Larsen; Lone Helboe; Søren Christensen; Lars O Pedersen; Mette Nielsen; Lars Torup; Thomas Sager; Alessandra Sfacteria; Serhat Erbayraktar; Zubeyde Erbayraktar; Necati Gokmen; Osman Yilmaz; Carla Cerami-Hand; Qiao-Wen Xie; Thomas Coleman; Anthony Cerami; Michael Brines Journal: Science Date: 2004-07-09 Impact factor: 47.728
Authors: Hannelore Ehrenreich; Karin Weissenborn; Hilmar Prange; Dietmar Schneider; Christian Weimar; Katja Wartenberg; Peter D Schellinger; Matthias Bohn; Harald Becker; Martin Wegrzyn; Peter Jähnig; Manfred Herrmann; Michael Knauth; Mathias Bähr; Wolfgang Heide; Armin Wagner; Stefan Schwab; Heinz Reichmann; Günther Schwendemann; Reinhard Dengler; Andreas Kastrup; Claudia Bartels Journal: Stroke Date: 2009-10-15 Impact factor: 7.914
Authors: Michael Brines; Giovanni Grasso; Fabio Fiordaliso; Alessandra Sfacteria; Pietro Ghezzi; Maddalena Fratelli; Roberto Latini; Qiao-Wen Xie; John Smart; Chiao-Ju Su-Rick; Eileen Pobre; Deborah Diaz; Daniel Gomez; Carla Hand; Thomas Coleman; Anthony Cerami Journal: Proc Natl Acad Sci U S A Date: 2004-09-29 Impact factor: 11.205
Authors: Maotao He; Farooqahmed S Kittur; Chiu-Yueh Hung; Jianhui Zhang; Li Jing; David C Sane; P Andy Li; Jiahua Xie Journal: Transl Stroke Res Date: 2021-09-22 Impact factor: 6.829